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We read with interest the paper by 
Park et al. [1] investigating the associa-
tion between hydrochlorothiazide and 
non-melanoma and melanoma skin 
cancer in South Korean patients. We 
were, however, surprised to read that 
hydrochlorothiazide use was inversely 
associated with skin cancer risk. This 
contradicts previous studies [2,3], the 
underlying biological rationale based 
on hydrochlorothiazide’s known pho-
tosensitizing properties, as well as con-
clusions reached by medicines regula-
tors [4]. We believe, however, that these 
contrasting findings arise due to bias in 
the study design. 
In the study, Park et al. [1] follow pa-
tients from their first antihypertensive 
prescription which, as described, may 
not be a prescription for hydrochlorothi-
azide in the hydrochlorothiazide exposed 
group. Hydrochlorothiazide is often pre-
scribed in combination with other anti-
hypertensives and may therefore be less 
likely to be prescribed first-line. In the 
absence of a time-varying analysis, this 
will induce immortal time bias in the 
hydrochlorothiazide user group.
Patients were followed until the last 
day of data capture or the day of the 
first diagnosis of skin cancer. Exposure 
to hydrochlorothiazide was analyzed as 
having at least three hydrochlorothi-
azide prescriptions filled throughout 
that patient’s total follow-up. However, 
the duration of follow-up is shorter for 
patients receiving a skin cancer diag-
nosis (as this censor follow-up). Having 
filled ≥ 50,000 mg of hydrochlorothia-
zide (the highest strata in the dose-re-
sponse analyses) will, with a high dose 
of 25 mg/day, take > 5 years, or with 
12.5 mg/day > 10 years. This has to be 
achieved within the maximum study 
period of 7.5 years (January 2009 to June 
2017). As such, achieving such cumu-
lative hydrochlorothiazide exposure 
levels is equivalent to requiring the 
near-total absence of a censoring event. 
Such bias will be much more pro-
nounced in the dose-response analyses 
and corresponds quite well to the find-
ing that exposure yields a very strong 
‘protective’ effect against skin cancer. 
Whether these issues have been 
correctly identified, and whether they 
explain the findings or not, can eas-
ily be tested by the authors. First, any 
antihypertensive drug should display 
similar properties, that is, if the authors 
performs similar cumulative analyses 
using their design for e.g., angioten-
sin-converting enzyme inhibitors or 
calcium channel blockers, we would 
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expect them to identify similar protective associations. 
Second, hydrochlorothiazide use should be handled as a 
time-varying exposure. As such, each individual should 
contribute to the non-hydrochlorothiazide cohort from 
the time of the first antihypertensive prescription until 
the time of the first hydrochlorothiazide prescription. 
From the time of the first hydrochlorothiazide prescrip-
tion, that person should contribute person-time to the 
hydrochlorothiazide user group only. If person-time is 
handled in this way, we would expect the protective as-
sociations obtained for ‘ever use of hydrochlorothiazide’ 
to vanish. 
Nevertheless, we may not expect to see similar risks 
observed in a European population [2,3] replicated in an 
Asian population. In fact, in a recent Taiwanese study, 
hydrochlorothiazide showed no significant association 
to skin cancer [5]. This may be explained by several fac-
tors, including differences in skin phenotype, use of low-
er hydrochlorothiazide doses, and cultural differences in 
sun behavior. However, additional studies in Asian pop-
ulations are necessary to confirm these findings.
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